• Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • NP and PA
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
  • Vitiligo
  • Wound Care

Opinion

Video

Transitioning Patients from Traditional Immunosuppressive Agents to JAK Inhibitor

Experts offer their clinical advice on when and how to transition patients from a biologic or immunosuppressive agent to a Janus Kinase (JAK) inhibitor.

Video Player is loading.
Current Time 0:00
Duration 5:32
Loaded: 0%
Stream Type LIVE
Remaining Time 5:32
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Christopher Bunick, MD, PhD

    Associate Professor, Dermatologist

    Yale University

    Middlebury, Connecticut

    Ruth Ann Vleugels, MD, MPD, MBA

    Vice-Chair of Academic Affairs

    Department of Dermatology at Brigham and Women’s Hospital

    Boston, Massachusetts

    Program Description: Experts discuss the results of multiple studies analyzing the incident rates and safety of Janus Kinase (JAK) inhibitors in the treatment of atopic dermatitis (AD).

    Segment Description: Experts offer their clinical advice on when and how to transition patients from a biologic or immunosuppressive agent to a Janus Kinase (JAK) inhibitor.

    Newsletter

    Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

    © 2025 MJH Life Sciences

    All rights reserved.